Key Takeaways From Pfizer Analyst Ratings
Portfolio Pulse from Benzinga Insights
In the past three months, 11 analysts have rated Pfizer (NYSE:PFE), with most being somewhat bullish. The average 12-month price target increased by 3.13% to $38.82. Analysts' ratings reflect their reactions to market conditions and Pfizer's performance. Despite Pfizer's strong market presence, it faces challenges in profitability and asset utilization.
October 03, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer has received mostly somewhat bullish ratings from analysts, with an average price target increase of 3.13% to $38.82. Despite this, the company faces challenges in profitability and asset utilization.
The increase in the average price target and the majority of somewhat bullish ratings suggest a positive short-term outlook for Pfizer's stock. However, the company's challenges in profitability and asset utilization may temper this optimism.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100